JP2005524399A5 - - Google Patents

Download PDF

Info

Publication number
JP2005524399A5
JP2005524399A5 JP2004501579A JP2004501579A JP2005524399A5 JP 2005524399 A5 JP2005524399 A5 JP 2005524399A5 JP 2004501579 A JP2004501579 A JP 2004501579A JP 2004501579 A JP2004501579 A JP 2004501579A JP 2005524399 A5 JP2005524399 A5 JP 2005524399A5
Authority
JP
Japan
Prior art keywords
cancer cells
alcam
pharmaceutical composition
ability
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2004501579A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005524399A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/014025 external-priority patent/WO2003093443A2/en
Publication of JP2005524399A publication Critical patent/JP2005524399A/ja
Publication of JP2005524399A5 publication Critical patent/JP2005524399A5/ja
Withdrawn legal-status Critical Current

Links

JP2004501579A 2002-05-03 2003-05-02 Ａｌｃａｍおよびａｌｃａｍ調節因子 Withdrawn JP2005524399A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37747902P 2002-05-03 2002-05-03
PCT/US2003/014025 WO2003093443A2 (en) 2002-05-03 2003-05-02 Alcam and alcam modulators

Publications (2)

Publication Number Publication Date
JP2005524399A JP2005524399A (ja) 2005-08-18
JP2005524399A5 true JP2005524399A5 (https=) 2006-03-16

Family

ID=29401505

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004501579A Withdrawn JP2005524399A (ja) 2002-05-03 2003-05-02 Ａｌｃａｍおよびａｌｃａｍ調節因子

Country Status (7)

Country Link
US (1) US20040048319A1 (https=)
EP (1) EP1501544A4 (https=)
JP (1) JP2005524399A (https=)
CN (1) CN1662254A (https=)
AU (1) AU2003225294A1 (https=)
CA (1) CA2483912A1 (https=)
WO (1) WO2003093443A2 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005111623A1 (en) * 2004-05-17 2005-11-24 Crucell Holland B.V. Methods for diagnosis of acute myeloid leukemia
WO2006084075A2 (en) * 2005-02-02 2006-08-10 Raven Biotechnologies, Inc. Adam-9 modulators
WO2008063479A2 (en) * 2006-11-17 2008-05-29 Fred Hutchinson Cancer Research Center Pancreatic cancer biomarkers
GB0705775D0 (en) * 2007-03-26 2007-05-02 Affitech As Product
US20100216652A1 (en) * 2007-04-25 2010-08-26 The Trustees Of The Universit Of Pennsylvania Low Level Fluorescence Detection at the Light Microscopic Level
EP2065399A1 (en) * 2007-11-30 2009-06-03 Siemens Healthcare Diagnostics GmbH The present invention relates to methods for prediction of the therapeutic success of breast cancer therapy
US20110151580A1 (en) * 2007-11-06 2011-06-23 University Health Network Method for the detection of breast cancer by determining alcam and/or bcam levels in a patient
EP2215251A2 (en) 2007-11-30 2010-08-11 Siemens Healthcare Diagnostics GmbH Method for predicting therapy responsiveness in basal like tumors
DK2786762T3 (da) 2008-12-19 2019-05-06 Macrogenics Inc Kovalente diabodies og anvendelser deraf
SG168430A1 (en) * 2009-07-22 2011-02-28 Agency Science Tech & Res Molecular signature of human lung cancer initiating cells
EP2542256B1 (en) 2010-03-04 2019-05-22 MacroGenics, Inc. Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
AU2011286024B2 (en) 2010-08-02 2014-08-07 Macrogenics, Inc. Covalent diabodies and uses thereof
KR101213445B1 (ko) 2011-01-13 2012-12-18 강원대학교산학협력단 백혈구의 혈관외유출 억제 활성 및 암세포의 전이 억제 활성을 갖는 펩타이드를 포함하는 약학 조성물
BR112013029892A2 (pt) 2011-05-21 2016-12-20 Macrogenics Inc polipeptídeo, molécula de ligação a antígeno, diacorpo e uso de uma porção polipeptídica de uma proteína de ligação a soro desimunizada
WO2013033734A1 (en) 2011-09-02 2013-03-07 The Trustees Of Columbia University In The City Of New York Diagnosis and Treatment of Cancer Expressing ILT3 or ILT3 Ligand
WO2014059372A1 (en) * 2012-10-11 2014-04-17 Vanderbilt University Characterization of cancer using detection of activated leukocyte cell adhesion molecule (alcam) shedding
US10451628B2 (en) 2014-05-07 2019-10-22 University Of Utah Research Foundation Biomarkers and methods for diagnosis of early stage pancreatic ductal adenocarcinoma
EA035419B9 (ru) 2014-05-29 2020-08-07 Мэкроудженикс, Инк. Триспецифичные связывающие молекулы и способы их применения
IL292798A (en) 2015-05-04 2022-07-01 Cytomx Therapeutics Inc Anti-cd166 antibodies, activatable anti-cd166 antibodies, preparations containing them and their uses
WO2017015227A1 (en) * 2015-07-17 2017-01-26 The Trustees Of Columbia University In The City Of New York Methods of treating cd166-expressing cancer
HUE068868T2 (hu) 2015-07-30 2025-02-28 Macrogenics Inc PD-1-hez kötõdõ molekulák és alkalmazásukra szolgáló eljárások
IL260021B (en) 2015-12-14 2022-09-01 Macrogenics Inc Bispecific molecules that are immunoreactive for pd1 and ctla4 and methods for using them
AU2018224094B2 (en) 2017-02-24 2025-04-17 Macrogenics, Inc. Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
CN111133006A (zh) 2017-07-14 2020-05-08 西托姆克斯治疗公司 抗cd166抗体及其用途
KR20200098590A (ko) 2017-12-12 2020-08-20 마크로제닉스, 인크. 이중특이적 cd16-결합 분자 및 질환 치료에서의 그것의 용도
JP7337079B2 (ja) 2018-02-15 2023-09-01 マクロジェニクス，インコーポレーテッド 変異型ｃｄ３結合ドメイン、及び疾患の治療のための併用療法におけるその使用
WO2020072761A1 (en) * 2018-10-05 2020-04-09 The Regents Of The University Of Michigan Compositions and methods for treating cancer

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6054561A (en) * 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
US5807715A (en) * 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
IE62463B1 (en) * 1988-07-07 1995-02-08 Res Dev Foundation Immunoconjugates for cancer diagnosis and therapy
US5552391A (en) * 1990-01-16 1996-09-03 La Jolla Pharmaceutical Company Chemically-defined non-polymeric valency platform molecules and conjugates thereof
US5427908A (en) * 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5846535A (en) * 1990-10-12 1998-12-08 The United States Of America As Represented By The Department Of Health And Human Services Methods for reducing tumor cell growth by using antibodies with broad tumor reactivity and limited normal tissue reactivity
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
GB9115364D0 (en) * 1991-07-16 1991-08-28 Wellcome Found Antibody
AU669124B2 (en) * 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
US5565332A (en) * 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5714350A (en) * 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5733743A (en) * 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US6210671B1 (en) * 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
US6180377B1 (en) * 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
WO1995012614A1 (en) * 1993-11-02 1995-05-11 Duke University Cd6 ligand
US5968768A (en) * 1993-11-02 1999-10-19 Duke University CD6 ligand encoding sequence
US5998172A (en) * 1993-11-02 1999-12-07 Duke University Anti-CD6 ligand antibodies
US5532159A (en) * 1994-04-01 1996-07-02 The Ohio State University Monoclonal antibody to canine placental oncofetal protein for detecting cancer
US6265150B1 (en) * 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
WO1998043089A1 (en) * 1997-03-03 1998-10-01 Bristol-Myers Squibb Company Monoclonal antibodies to human cd6
AU9127098A (en) * 1997-09-04 1999-03-22 Osiris Therapeutics, Inc. Ligands that modulate differentiation of mesenchymal stem cells
FR2796073B1 (fr) * 1999-07-07 2003-08-29 Centre Nat Rech Scient Anticorps anti-idiotypiques des facteurs de croissance des fibroblastes et leur utilisation comme medicaments
US6441163B1 (en) * 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents

Similar Documents

Publication Publication Date Title
JP2005524399A5 (https=)
JP5109031B2 (ja) 細胞結合性ｃａ１２５／ｏ７７２ｐに結合する抗体およびその使用方法
CN113924103B (zh) 用于用自驱动的嵌合抗原受体来治疗癌症的组合物和方法
Dohlsten et al. Antibody-targeted superantigens are potent inducers of tumor-infiltrating T lymphocytes in vivo.
JP2019107018A5 (https=)
JP2008529497A5 (https=)
JP2023547323A5 (https=)
UA104130C2 (uk) Антитіло, що специфічно зв'язується з il-4 і іl-13 та спосіб лікування астми у ссавця за допомогою такого антитіла
JP2007504280A5 (https=)
JP2010508847A5 (https=)
RU2007133108A (ru) АНТИТЕЛА, СВЯЗЫВАЮЩИЕСЯ С EphA2, И МЕТОДЫ ИХ ИСПОЛЬЗОВАНИЯ
JP2005505256A5 (https=)
JP2006514024A5 (https=)
TWI726217B (zh) 含有抗globo h抗體之抗體－藥物共軛物及其用途
WO2011137687A1 (zh) 一种抗癌胚抗原抗体及其应用
CN102027014A (zh) 用于治疗癌症的新抗体
EP4130046A1 (en) Platform for constructing multispecific antibody
CN111825766B (zh) 抗il-4r单域抗体及其应用
JP2024512858A (ja) 抗ｔｓｌｐナノ抗体およびその使用
EP3313871A1 (en) Proteins comprising a mutated lair-1 fragment and uses thereof
Zhu et al. Research progress on HER2-specific chimeric antigen receptor T cells for immunotherapy of solid tumors
CN117177999B (zh) 一种靶向IL-18Rβ的抗体及其应用
CN110139661A (zh) Igfb3及其受体相关疾病的治疗
WO2023066389A1 (zh) 靶向pd-1的双特异性抗体、及其制备和应用
Luiten et al. Generation of chimeric bispecific G250/anti-CD3 monoclonal antibody, a tool to combat renal cell carcinoma